Clinical Trial Update: Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating Veregen 10% Ointment as a topical treatment for actinic keratosis of the face and scalp, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• Veregen 10% Ointment (sinecatechin)

Snippet

Sponsor: Aresus Pharma GmbH | Conditions: Actinic Keratosis of Face and Scalp | Phase 3 | Status: RECRUITING